Evidence map›Paper›PMID 40284983›Full record

ArticleViruses2025

An In-Depth Characterization of SARS-CoV-2 Omicron Lineages and Clinical Presentation in Adult Population Distinguished by Immune Status.

Greta Marchegiani, Luca Carioti, Luigi Coppola, Marco Iannetta, Leonardo Alborghetti, Vincenzo Malagnino, Livia Benedetti, Maria Mercedes Santoro, Massimo Andreoni, Loredana Sarmati and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Greta MarchegianiDepartment of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0009-0006-7878-2833
Luca CariotiDepartment of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-1713-8682
Luigi CoppolaClinical Infectious Disease, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0009-0005-4728-261X
Marco IannettaClinical Infectious Disease, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-6938-8627
Leonardo AlborghettiClinical Infectious Disease, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Vincenzo MalagninoClinical Infectious Disease, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-6561-5298
Livia BenedettiClinical Infectious Disease, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Maria Mercedes SantoroDepartment of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-6228-1114
Massimo AndreoniClinical Infectious Disease, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Loredana SarmatiClinical Infectious Disease, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-1452-0333
Claudia AlteriDepartment of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
Francesca Ceccherini-SilbersteinDepartment of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Maria Concetta BellocchiDepartment of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0001-7717-2343

Funding

EuCARE Project funded by the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement No 101046016 and on behalf of SARS-CoV-2 ITALIAN RESEARCH ENTERPRISE-(SCIRE) Collabora-tive Group from the Ministero dell'Università e del No 101046016 and PRIN 202022GZEHE_01
6 · The paper itself

Abstract

This retrospective study analyzed SARS-CoV-2 Omicron variability since its emergence, focusing on immunocompromised (IPs) and non-immunocompromised adult people (NIPs). Phylogenetic analysis identified at least five major Omicron lineage groups circulating in Central Italy, from December 2021 to December 2023: (a) BA.1 (34.0%), (b) BA.2 + BA.4 (25.8%), (c) BA.5 + BF (10.8%), (d) BQ + BE + EF (9.2%), and (e) Recombinants (20.2%). The BA.2 + BA.4 lineages were more common in IPs compared to NIPs (30.9% vs. 17.8%, respectively;

Indexed as

COVID-19SARS-CoV-2AdultAgedAged, 80 and overFemaleHumansImmunocompromised HostItalyMaleMiddle AgedPhylogenyPolymorphism, Single NucleotideRetrospective StudiesSpike Glycoprotein, CoronavirusYoung AdultSpike Glycoprotein, Coronavirusgenetic variabilityhospitalizationSARS-CoV-2 Omicron

Identifiers

PMID40284983
PMCPMC12031151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.